NCT07508046Completed
Clinical Study on the Expression of PHGDH and Its Prognostic Value in Colorectal Cancer Patients Receiving Immunotherapy
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
This study aims to evaluate the expression characteristics of PHGDH in tumor tissues based on the clinical data and pathological tissue samples of colorectal cancer patients who have previously received immunotherapy, and to analyze its correlation with patients' clinical features, immunotherapy efficacy, and survival prognosis, providing a basis for clarifying the clinical relevance of PHGDH.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 27 Mar 2026
- Start date
- 1 Nov 2025
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- West China Hospital
- Diseases
- Colorectal cancer, Childhood cancers
- NCT number
- NCT07508046
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 1 Nov 2025 to the primary completion date, 1 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Permanently discontinued immunotherapy prior to the first scheduled radiological response assessment.
Other illness
- History of other active malignancies within the past 5 years (except for adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix).
Other
- Unavailability of adequate tumor tissue for PHGDH expression analysis.
- Insufficient clinical documentation to determine the primary outcome (e.g., progression-free survival).
Who the study is looking for
- Patients with histologically confirmed colorectal adenocarcinoma.
- Initiated treatment with immune checkpoint inhibitors (at least one cycle) between June 1, 2018 and December 31, 2025.
- Availability of pre-treatment archival tumor tissue (FFPE block or slides) for PHGDH immunohistochemistry testing.
- Have evaluable baseline radiographic images (CT or MRI) prior to immunotherapy.
- Sufficient medical records for survival follow-up data extraction.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West China Hospital Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.